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Tyrosine kinase inhibitors such as imatinib, dasatinib, and nilotinib interfere with ATP-binding pocket to
inhibit BCR-ABL1 kinase. A recent report in Cell by Grebien et al. paves the way for a new approach to target
BCR-ABL1 kinase by interfering with its SH2-kinase domain interface.BCR-ABL1 fusion tyrosine kinase results
from a reciprocal chromosomal translo-
cation between chromosomes 9 and 22,
producing the Philadelphia chromosome.
BCR-ABL1 is expressed in chronic mye-
loid leukemia (CML) and a cohort of acute
lymphocytic leukemia. BCR-ABL1 kinase
triggers CML in chronic phase (CML-CP)
when expressed in hematopoietic stem
cells, but uncontrolled proliferation of
BCR-ABL1-positive progenitors is re-
sponsible for manifestation of the dis-
ease (Marley and Gordon, 2005). The
ability of BCR-ABL1 kinase to induce
a CML-like disease in mouse models
and the anti-leukemia effect of BCR-
ABL1-specific antisense oligonucleotides
indicated that BCR-ABL1 kinase shouldFigure 1. Targeting the SH2-Kinase Domain Interface
in BCR-ABL1
Cartoon diagram of the SH2-kinase domain interface under-
lining the critical role of Ile164 (I164). The 7c12 monobody
interferes with the I164 to inhibit BCR-ABL1 kinase activity.be targeted in CML patients (Daley
et al., 1990; Skorski et al., 1994).
Imatinib, a small molecule tyrosine
kinase inhibitor (TKI) of the ABL1
kinase revolutionized the treatment
of CML (Druker et al., 1996). Imatinib,
an ATP-competitive inhibitor, is the
first choice drug in CML-CP,
because of its high efficacy, low
toxicity and ability to maintain du-
rable remissions. However, a sig-
nificant number of patients initially
treated with imatinib will develop
drug resistance, which is often
caused by the appearance of clones
expressing mutant forms of BCR-
ABL1. More than 50 imatinib-resis-
tant BCR-ABL1 kinase domain mu-
tations (for example, Y253F/H,
E255K, T315I, M351T, H396R) were
detected in CML patients who re-
lapsed after initial response to imati-
nib (Shah et al., 2002). These mu-
tations directly prevent imatinib
binding or affect the ability of the
kinase to achieve the conformation1352 Chemistry & Biology 18, November 23,required to bind imatinib. This spurred the
research to generate TKIs, which would
also inhibit imatinib-resistant BCR-ABL1
kinase mutants.
Dasatinib and nilotinib, the two repre-
sentatives of ATP-competitive second-
generation TKIs (2G-TKIs), have been
successfully applied in patients resis-
tant to imatinib (Santos and Quinta´s-
Cardama, 2011). However, none of the
2G-TKIs were able to inhibit the BCR-
ABL1 T315I gatekeeper mutant. Third-
generation TKIs (3G-TKIs) such as DCC-
2036, which binds to the ‘‘switch pocket’’
that govern the transition between the
active and the inactive states of ABL1
kinase, and AP24534, which avoids the
interaction with the side chain of T315,2011 ª2011 Elsevier Ltd All rights reservedretain the efficacy against the clinically
relevant BCR-ABL1 kinase mutants, in-
cluding T315I, and are currently in clinical
trials. In addition, the myristoyl pocket
located near the carboxy-terminal lobe
of the ABL1 kinase domain could be tar-
geted by GNF-2 and its analogs to inhibit
BCR-ABL1 kinase activity through an allo-
steric non-ATP-competitive mechanism
(Zhang et al., 2010). Moreover, GNF-2,
when used in combination with the ATP-
competitive inhibitors, displayed an addi-
tive inhibitory effect against T315I mutant.
However, BCR-ABL1 kinase mutants
resistant to the 3G-TKIs will likely develop
(Eide et al., 2011), and targeting other
sites on BCR-ABL1 itself may improve
future therapeutic options. BCR-ABL1kinase consists of numerous do-
mains regulating its leukemogenic
activity, including an SH2 domain.
In addition to their role in protein-
protein interaction, SH2 domains
in certain kinases, like ABL1, were
shown to activate the adjacent tyro-
sine kinase domain. The ability of
the SH2 domain to stimulate ABL1
kinase activity depended on the
establishment of a tight interface
between the SH2 domain and the
N-terminal lobe of the kinase do-
main. In the recent paper in Cell,
Florian Grebien, Oliver Hantschel
and colleagues from Giulio Superti-
Furga’s laboratory (Grebien et al.,
2011) showed that an intramolecular
interaction between the SH2
domain and the kinase domain in
BCR-ABL1 triggers high catalytic
activity of the kinase. Interestingly,
the T231R mutation in the SH2
domain of the BCR-ABL1 was
implicated in imatinib resistance.
This mutation may stabilize the
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the I164E mutation located in the aA-bB-
loop of the SH2 domain negated the allo-
steric activation of the BCR-ABL1 kinase
by disrupting the SH2-kinase domain
interface. Therefore, the SH2-kinase
domain interface appears to play a critical
structural role in adopting andmaintaining
of the active conformation of BCR-ABL1
kinase. In addition, the BCR-ABL I164E
mutant did not induce leukemia in mice,
revealing a critical role of the BCR-ABL1
SH2-kinase interface in leukemogenesis.
This effect might depend on the almost
exclusive lack of activation of STAT5, but
not PI3k-Akt and Ras-MAPK pathways,
by the BCR-ABL I164E mutant. Impor-
tantly, disruption of the SH2-kinase
domain interface by I164E not only sensi-
tized BCR-ABL1 to imatinib and nilotinib
but also enhanced inhibition of TKI resis-
tant BCR-ABL1 mutants including T315I.
To test if the SH2-kinase domain in-
terface is ‘‘druggable,’’ a single-domain
binding protein (monobody) called 7c12,
which interacts with the interface, was
generated by phage-display library sort-
ing (Figure 1). 7c12 exerted an inhibitory
effect on BCR-ABL1 and T315I mutant
kinase activities; the inhibition was im-
provedwhen 7c12 was fused with a previ-ously generated HA4 monobody, which
interacts with the SH2 phosphotyrosine-
binding pocket. The HA4-7c12 tandem
monobody inhibitedBCR-ABL1-mediated
transformation and induced apoptosis in
CML patient cells.
In conclusion, the SH2-kinase domain
interface appears to play an essential role
in the achievement and maintenance
of the active conformation of BCR-ABL1
kinase and is also critical for BCR-ABL1-
mediated leukemogenesis probably due
to activation of STAT5. Moreover, interfer-
ence with the SH2-kinase domain inter-
face induced apoptosis in primary CML
cells. Thus, in addition to the ATP- and
myristate-binding sites, the SH2-kinase
domain interface in BCR-ABL1 repre-
sents a potential ‘‘druggable’’ target for
novel small molecule inhibitors. However,
given the high mutagenic activity in CML
cells, drug resistant mutants may emerge
during therapy with the use of new
compounds disrupting the SH2-kinase
domain interface (Koptyra et al., 2006).
Therefore, one could ask if anti-BCR-
ABL1 kinase small molecule inhibitor
therapy should be combined with drugs
that inhibit genomic instability and prevent
the appearance of resistant BCR-ABL1
mutants.Chemistry & Biology 18, November 23, 2011 ªREFERENCES
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